Ines Verdon joined Rubius as Vice President, Clinical Development in April 2021. She oversees the development, strategy and execution of several clinical development programs at Rubius.
Ines brings more than 20 years of academic and pharmaceutical experience in clinical development in the areas of oncology, infectious disease, cardiovascular disease and molecular diagnostics. She also has experience across drug safety and pharmacovigilance, as well as medical training in cardiothoracic, general surgery, and intensive care.
During her career, Ines has served as the Senior Medical Lead as well as Global Safety Lead on Phase I, II and III clinical trials. Most recently, Ines joined Rubius from Sierra Oncology where she was the Medical Lead in Oncology for Phase III and Phase I/II clinical trials. Before that, Ines was the Medical Director at Onyx, a subsidiary of Amgen, and held positions at Gilead and Epigenomics earlier in her career.
Ines holds an M.D. from Goethe‐University in Frankfurt, Germany and completed a doctoral thesis in the Department of Pharmacology at the University of Bonn, Germany. She also held a postdoctoral research fellowship position in the Department of Surgery at the University of California, San Francisco.